Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)

Lessons Learned Results suggest that the combination of bevacizumab plus temozolomide is active in terms of response rate, survival, performance, quality of life, and cognition in elderly patients with glioblastoma multiforme with poor performance status. Whether this combination is superior to temo...

Full description

Saved in:
Bibliographic Details
Published in:The oncologist (Dayton, Ohio) Ohio), 2018-05, Vol.23 (5), p.524-e44
Main Authors: Reyes‐Botero, Germán, Cartalat‐Carel, Stéphanie, Chinot, Olivier L., Barrie, Maryline, Taillandier, Luc, Beauchesne, Patrick, Catry‐Thomas, Isabelle, Barrière, Jérôme, Guillamo, Jean‐Sebastien, Fabbro, Michel, Frappaz, Didier, Benouaich‐Amiel, Alexandra, Le Rhun, Emilie, Campello, Chantal, Tennevet, Isabelle, Ghiringhelli, François, Tanguy, Marie‐Laure, Mokhtari, Karima, Honnorat, Jérôme, Delattre, Jean‐Yves
Format: Article
Language:English
Subjects:
Cancer
Clinical Trial Results
Life Sciences
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lessons Learned Results suggest that the combination of bevacizumab plus temozolomide is active in terms of response rate, survival, performance, quality of life, and cognition in elderly patients with glioblastoma multiforme with poor performance status. Whether this combination is superior to temozolomide alone remains to be demonstrated by a randomized study. Background The optimal treatment of glioblastoma multiforme (GBM) in patients aged ≥70 years with a Karnofsky performance status (KPS)
ISSN:1083-7159
1549-490X
DOI:10.1634/theoncologist.2017-0689